retatrutide black market for weight loss: Study shows 30% body weight loss Retatrutide Black Market: Why Consumers

Early trials suggest Retatrutide may be more potent, but its still under study

En ambos casos, aproximadamente el 5-10% de pacientes pierden menos del 5% de su peso corporal, incluso con dosis adecuadas

A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials

It may be a better fit for patients seeking more robust weight loss potential, patients with stronger appetite signals, or patients who did not get their desired response from semaglutide

Significant reductions in body weight and improvements in glycaemic control have been demonstrated in early-phase clinical trials, most notably the Phase 2 trial published in the New England Journal of Medicine in 2023 (Jastreboff et al., NEJM 2023)